<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02221622</url>
  </required_header>
  <id_info>
    <org_study_id>AlloPhase1</org_study_id>
    <secondary_id>1UF1AG046148</secondary_id>
    <nct_id>NCT02221622</nct_id>
  </id_info>
  <brief_title>Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD</brief_title>
  <acronym>Allo</acronym>
  <official_title>Allopregnanolone Regenerative Therapeutic for MCI/AD: Dose Finding Phase 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of allopregnanolone, a
      naturally occurring brain steroid, in mild cognitive impairment and early Alzheimer's disease
      participants. The primary goal is to determine the maximally tolerated dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1) Each dose group will be comprised of 8 participants (6 randomized to allopregnanolone; 2
      randomized to placebo) administered one dose of allopregnanolone or placebo once per week for
      12 weeks. A higher dose will be administered to the next group of participants when the lower
      dose is shown to be safe and tolerable. 2) Pharmacokinetic analyses will be conducted on
      blood samples taken from participants at the beginning and end of the trial. 3) The trial
      will assess safety including via MRI brain imaging.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as measured by vital signs, clinical laboratory measurements, adverse events, brain MRI, clinical assessment and examination.</measure>
    <time_frame>From Baseline to Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile after single and multiple doses: Maximum Concentration (Cmax)</measure>
    <time_frame>Weeks: 1 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile after single and multiple doses: time attain to Cmax (Tmax)</measure>
    <time_frame>Weeks: 1 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile after single and multiple doses: Area under the curve (AUC)</measure>
    <time_frame>Weeks: 1 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile after single and multiple doses: Drug Clearance (CL)</measure>
    <time_frame>Weeks: 1 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile after single and multiple doses: apparent volume of distribution at steady state (Vss)</measure>
    <time_frame>Weeks: 1 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive tests (ADAS-Cog; MMSE/MoCA; ADCS-CGIC; CogState)</measure>
    <time_frame>Baseline to Week 13</time_frame>
    <description>Alzheimer's disease Assessment Scale Cognitive Subscale 14 (ADAS-Cog); Mini-Mental State Exam (MMSE); Montreal Cognitive Assessment (MoCA); Alzheimer's disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC); CogState 12-min battery (CogState)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural and functional brain MRI</measure>
    <time_frame>Baseline and Week 13</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Allopregnanolone 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopregnanolone 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopregnanolone 6-18 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo injection (intravenous solution) once per week for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopregnanolone injection (intravenous solution)</intervention_name>
    <description>Allopregnanolone intravenous infusion</description>
    <arm_group_label>Allopregnanolone 2 mg</arm_group_label>
    <arm_group_label>Allopregnanolone 4 mg</arm_group_label>
    <arm_group_label>Allopregnanolone 6-18 mg</arm_group_label>
    <other_name>3α,5α-tetrahydroprogesterone</other_name>
    <other_name>3α-hydroxy-5α-pregnan-20-one</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo injection (intravenous solution)</intervention_name>
    <description>Placebo intravenous infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or postmenopausal women

          -  55 years of age or older

          -  Diagnosis of MCI due to AD or mild AD

          -  MMSE &gt; 20 at screen

          -  Capacity to provide informed consent

          -  Residing in the community with a caregiver able to accompany the patient to clinic
             visits

          -  No medical contraindications to participation

          -  Willingness to comply with study procedures

        Exclusion Criteria:

          -  Use of benzodiazepines, sedative/hypnotics, anticonvulsants, antipsychotics, and other
             drugs that might interact with the GABA-A receptor complex

          -  Seizure disorder, history of stroke, focal brain lesion, traumatic brain injury,
             substance abuse, malignancy

          -  Clinically significant laboratory or ECG abnormality

          -  MRI indicative of any other significant abnormality, including but not limited to
             evidence of a cerebral contusion, encephalomalacia, aneurysms, vascular malformations,
             subdural hematoma, or space occupying lesions

          -  Any condition that would contraindicate an MRI such as the presence of metallic
             objects in the eyes, skin, heart, or body
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberta Diaz Brinton, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lon S. Schneider, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerson Hernandez</last_name>
    <phone>(323) 865-ALLO (323) 865-2556</phone>
    <email>gersonhe@usc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gerson Hernandez</last_name>
    <phone>(323) 442-7608</phone>
    <email>gersonhe@usc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Southern California - Alzheimer Disease Research Center - Healthcare Consultation Center II</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>August 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2014</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Roberta Brinton</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Dementia</keyword>
  <keyword>Regenerative therapeutic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Pregnanolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

